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Abstract
Background: Synuclein gamma (SNCG), initially identified as a breast cancer specific gene, is aberrantly expressed in 
many different malignant tumors but rarely expressed in matched nonneoplastic adjacent tissues. In this study, we 
investigated the prognostic potential of SNCG in colon cancer particularly in the patients with normal 
carcinoembryonic antigen (CEA) levels.
Methods: SNCG levels were assessed immunohistochemically in cancer tissues from 229 colon adenocarcinoma 
patients with a mean follow-up of 44 months. Correlations between SNCG levels and clinicopathologic features, 
preoperative serum CEA level, and clinical outcome were analyzed statistically using SPSS.
Results: SNCG levels in colon adenocarcinoma were closely associated with intravascular embolus and tumor 
recurrence but independent of preoperative serum CEA levels. SNCG expression was an independent prognostic factor 
of a shorter disease-free survival (DFS) and overall survival (OS) (P < 0.0001). Multivariate analysis revealed that both 
tissue SNCG and serum CEA were independent prognostic factors of DFS (P = 0.001, <0.0001, respectively) for 170 
patients with colon adenocarcinomas. Importantly, SNCG remained a prognostic determinant of DFS and OS (P = 0.001, 
0.002) for 97 patients with normal preoperative serum CEA level.
Conclusions: Our results suggest for the first time that SNCG is a new independent predicator for poor prognosis in 
patients with colon adenocarcinoma, including those with normal CEA levels. Combination of CEA with SNCG 
improves prognostic evaluation for patients with colon adenocarcinoma.
Background
Colorectal cancer (CRC) is one of the most common can-
cer types worldwide and it continues to be a serious pub-
lic health problem. Traditionally, TNM stage is the most
important predictor of survival for CRC patients, but cur-
rent classification of CRC can't predict prognosis pre-
cisely even for the patients in the same clinical stage.
Approximate 30% of stages I-II and 60% of stage III CRC
patients develop recurrence in two years after surgery [1].
I t is critical to find molecular signatures or factors for
predicting prognosis and for selecting high-risk patients
who need preventive chemotherapy or other adjuvant
therapies [2]. CEA is a widely used tumor markers world-
wide in CRC [3]. Serial monitoring of serum CEA for pre-
dicting recurrence and prognosis of CRC has been
established [4]. However, lack of sensitivity and specific-
ity preclude the use of CEA. Approximate 30% of all CRC
recurrences do not have elevated CEA serum levels [5].
Since any single marker is not sufficiently predictive,
combination of different markers representing different
aspects of tumor biology will have a better prognostic
evaluation [6,7]. Therefore, new cancer biomarkers or
better surveillance methods should be developed, evalu-
ated and standardized to improve the diagnostics of the
disease [1,4].
Synucleins are a family of small proteins consisting of 3
known members, synuclein α (SNCA), synuclein β
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(SNCB), and SNCG [8]. While synucleins are highly
expressed in neuronal cells and are abundant in presyn-
aptic terminals, SNCA and SNCB have been specifically
implicated in neurodegenerative diseases [9,10]. SNCG,
initially identified as a breast cancer specific gene [11], is
not clearly involved in neurodegenerative diseases but
primarily involved in neoplastic diseases [11-16]. SNCG
overexpression in breast cancer cells stimulates prolifera-
tion, induces metastasis, promotes chromosomal insta-
bility, inhibits mitotic checkpoint [12,17-19], and
increases resistance to certain chemotherapeutic or anti-
microtubule agents [20,21], however down-regulation of
SNCG expression sensitizes breast cancer cells to anti-
microtubule agents-induced cytotoxicity [20-22]. Being
identified as a breast cancer specific gene, SNCG is aber-
rantly expressed in malignant breast cancer cells but not
in the adjacent normal cells [16]. So far, the abnormal
expression of SNCG protein has been demonstrated in 12
different malignant diseases, including ovarian [13,23],
liver [15,24], esophagus [15], colon [15,25], gastric [15],
lung [15], prostate [15], pancreas [26], bladder [27], cervi-
cal cancers [15], and glial tumors[28]. In these studies,
SNCG protein is abnormally expressed in a high percent-
age of tumor tissues but rarely expressed in tumor-
matched nonneoplastic adjacent tissues.
The clinical relevance of SNCG expression on breast
cancer prognosis was confirmed in clinical follow-up
studies [16,29]. Patients with an SNCG-positive tumor
had a significantly shorter disease-free survival and over-
all survival compared with those with no SNCG expres-
sion. However, the prognostic significance of SNCG in
other cancers remains unknown. In the current study,
S N C G  l e v e l  a s  a s s e s s e d  b y  i m m u n o h i s t o c h e m i s t r y  o f
tumor sections is an independent prognostic factor of a
shorter DFS and OS for colon cancer patients. Impor-
tantly, SNCG remains a prognostic determinant of DFS
and OS for colon cancer patients with normal preopera-
tive serum CEA level.
Methods
Study Patients
Two hundred and twenty-nine colon adenocarcinoma tis-
sue, 194 corresponding non-neoplastic adjacent tissue,
and 37 colon adenoma, hyperplasia and polyp specimens
were obtained from the archives (1996-2003) of the
Department of Pathology, Peking University School of
Oncology. Specimens from patients were diagnosed his-
topathologically and staged according to the TNM-Inter-
national Union against Cancer classification system. The
clinicopathologic characteristics of patients were
described in Table 1. Among 229 colon cancer patients,
66 (28.8%) patients had tumor origin in the right colon,
16 (7%) patients had tumor origin in the transverse colon,
and 147 (64.2%) patients had tumor origin in the left
colon. None of the patients had received chemotherapy
or radiation therapy before surgery, and none of them had
a history of hereditary. Most primary tumors were
treated by surgical resection and 20 patients including 17
stage IV patients received palliative treatment. Age at
first diagnosis ranged from 23 to 85 years (mean ± SD,
60.6 ± 12.1). The mean follow-up length for these
patients was 44.1 ± 28.2 months ranged from 11 days to
121 months. During follow-up, 46.3% (106/229) patients
died of colon adenocarcinoma and 26.9% (61/229)
patients developed recurrence after surgery. Among the
patients with recurrence, liver metastasis was present in
28 of 61 (46%) cases, lung metastasis was present in 9 of
61 (15%), extensive intra-abdominal metastases in 11 of
61 (18%), and the rest recurrent lesions were in colon,
brain, bone, and ovary. Overall survival time was calcu-
lated from the date of surgery to the date of death due to
any cause. Disease-free survival (DFS) time was calcu-
lated for patients from the date of surgery to the date of
disease progression (local recurrence or distant metasta-
sis). Data on patients, who had survived until the end of
follow-up period, were censored at the date of last con-
tact. Informed consent was obtained from all of the
patients and healthy examinees. The study was approved
and supervised by the Medical Ethic Committee of Bei-
jing Cancer Hospital/Institute.
Immunohistochemistry
SNCG protein expression was analyzed by immunohis-
tochemical staining as the following procedures. Paraffin-
embedded whole tissue sections were deparaffinized with
xylene. Following rehydration in distilled water, antigen
was retrieved by heating in EDTA (pH 8.0, Zymed).
Endogenous peroxidase activity was blocked by incubat-
ing in 3% hydrogen peroxide at room temperature (RT)
for 10 minutes. Nonspecific binding was blocked with
PBST (0.01 mol/L PBS containing 0.05% Tween-20) con-
taining 10% goat serum and 3% skimmed milk for 2 h at
RT. Anti-SNCG mAb 1# [25] was applied to each slide
and incubated at RT for 2 h. Following three washes,
slides were incubated with Envision (DAKO) for 40 min-
utes at RT. Diaminobenzidine was used as a chromogen.
S e c t i o n s  w e r e  c o u n t e r s t a i n e d  w i t h  h e m a t o x y l i n ,  d e h y -
drated, and mounted. The quality, specificity, and sensi-
tivity of the assay were determined in reference 25. As a
positive control, a colon cancer tissue with confirmed
strong and SNCG specific staining in previous study [25]
was used, whereas the primary antibody was omitted for
a negative control.
Evaluation of Immunohistochemical Staining
Immunohistochemical expression was evaluated under
light microscopy (APPLIED IMAGING at 200×) inde-
pendently by two experienced pathologists (B Dong andLiu et al. BMC Cancer 2010, 10:359
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A Lu) without knowledge of the patients' backgrounds
and clinicopathologic data. There were 9 cases (3.9%) dis-
agreement on weak staining and the discrepancies were
resolved by simultaneous reevaluation. Immunoreactivity
for SNCG in tumour cells was graded as either negative
or positive according to a four-value classification scale as
follows: area of staining as <10 percent (0) or >10 percent
(1) of all cancer cells stained within the section, staining
intensity (>10% of all cancer cells stained within the sec-
tion) was graded as weak (1), moderate (2), or strong (3).
A total score for area adding grade of 3 or more was
defined as positive expression and less than 3 as negative.
To avoid inappropriate evaluation caused by variations of
background staining, all stained slides were reconciled
with negative control slides from the same tissue samples.
Table 1: Correlations of SNCG Expression with Clinicopathologic Factors and Their Influences on Postoperative Recurrence
Characteristics No. of cases SNCG expression No. of recurrence (%) HR (95%CI) P value
SNCG+ (%) P value
Gender
Male 121 38 (31.4) 0.066 28 (23.1) 1 0.205
Female 108 36 (33.3) 33 (30.6) 1.461 (0.811-2.632)
Age (yrs)
≤60 89 31 (34.8) 0.516 22 (24.7) 1 0.601
>60 140 43 (32.9) 39 (27.9) 1.176 (0.641-2.581)
Size (cm)
≤4 90 23 (25.6) 0.072 19 (21.1) 1 0.120
>4 138 51 (37.0) 42 (30.4) 1.635 (0.877-3.047)
TNM stage
I/II 114 32 (28.1) 0.172 14 (12.3) 1 0.000
III/IV 115 42 (36.5) 47 (40.9) 4.937 (2.522-9.663)
Depth of invasion
pT1 and pT2 39 12 (30.8) 0.821 4 (10.3) 1 0.011
pT3 190 62 (32.6) 57 (30.0) 3.750 (1.273-11.043)
Differentiation
WD and MD 192 61 (31.8) 0.689 49 (25.5) 1 0.384
PD 37 13 (35.1) 12 (32.4) 1.401 (0.654-2.998)
LN metastasis
Negative 125 37 (29.6) 0.336 20 (16.0) 1 0.000
Positive 104 37 (35.6) 41 (39.4) 3.417 (1.840-6.346)
Intravascular embolus
Negative 170 48 (28.2) 0.025 40 (23.5) 1 0.071
Positive 59 26 (44.1) 21 (35.6) 1.796 (0.947-3.406)
CEA
Negative 97 34 (35.1) 0.658 15 (15.5) 1 0.001
Positive 73 28 (38.4) 28 (38.4) 3.401 (1.648-7.023)
ND 59
SNCG
Negative 155 ---- ---- 34 (22.2) 1 0.020
Positive 74 ---- 27 (36.5) 2.044 (1.114-3.752)
WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated; LN, lymph node; HR, hazard ratio; CI, confidence interval; ND, 
Not Detected.Liu et al. BMC Cancer 2010, 10:359
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Preoperative CEA Value Determination
The preoperative serum levels of CEA were determined
by commercially available immunoassay ELISA kit
(Roche Diagnostics). The serum levels of CEA were con-
sidered positive when they were equal to or higher than
5.0 ng/ml (cutoff value) and negative when lower than
that according to the manufacture's instructions.
Data Analysis
Differences in SNCG protein expression between cancer
and non-cancer tissues in the same patient were analyzed
using a paired T test. Correlations between SNCG levels
and patient clinicopathologic characteristics, CEA levels
were performed using Pearson chi-square test. The
Kaplan-Meier method was used to estimate disease-free
survival (DFS) and overall survival (OS) rates, and the
survival differences were analyzed by Log rank test. The
Cox proportional hazard model was used for multivariate
analysis to investigate the independence of the risk fac-
tors identified as significant in the univariate analysis. All
statistical analyses were two-sided, and comparisons
made in which probability values less than 0.05 were con-
sidered statistically significant. All statistical analyses
were carried out using SPSS for Windows Software (ver-
sion 13.0).
Results
SNCG is overexpressed in colon adenocarcinoma cells and 
is associated with intravascular embolus
Using a previously characterized specific monoclonal
antibody for SNCG [25], we immunohistochemically ana-
lyzed SNCG expression in 460 clinical colon samples
including 37 benign adenoma, hyperplasia, and polyp tis-
sues, 229 colon adenocarcinomas, and 194 tumor-adja-
cent normal epithelium. As summarized in Table 2, none
of 37 benign lesions showed positive staining of SNCG. In
contrast, SNCG was aberrantly expressed in colon adeno-
carcinomas. SNCG expression in colon adenocarcinoma
was heterogeneous and varied greatly between different
cancer cells. As shown in Figure 1A, SNCG specifically
expressed in the cytoplasm of cancer cells, whereas no
expression observed in the adjacent normal epithelium.
Figure 1B, C, D represented the intensity of weak (1
score), moderate (2 scores) and strong (3 scores) staining
of SNCG in cancer cells. We also found that SNCG was
strongly expressed in colon neuron-chords, vascular
endothelial cells, and smooth muscle cells of nearly all
colon cancer specimens. While only 4 SNCG-positive
cases were detected in 194 tumor-adjacent normal tissues
(2.1%), moderate or strong expression of SNCG protein
was detectable in 74 of 229 colon cancer cases (32.3%).
Associations between SNCG expression and clinical
and biological tumor characteristics were analyzed (Table
1). Overall, there was no significant correlation between
SNCG protein expression and age, tumor size, tumor dif-
ferentiation, depth of invasion, TNM stage, and preoper-
ative serum CEA levels. However, expression of SNCG in
colon adenocarcinoma tissues was strongly correlated
with intravascular embolus (P = 0.025). Interestingly, in
c o n t r a s t  t o  p r e v i o u s  o b s e r v a t i o n s  o f  a n  a s s o c i a t i o n
between SNCG expression and tumor stage in many dif-
ferent cancers [11,15], levels of SNCG in colon adenocar-
cinoma tissues did not display any significant difference
between stages I-II and III-IV [28.1% (32/114) and 36.5%
(42/115), P = 0.172]. The associations between these fac-
tors and recurrence were also analyzed (Table 1). As
expected, clinicopathologic features including TNM
stage (P < 0.0001), lymph node metastasis (P < 0.0001),
depth of invasion (P = 0.011), preoperative serum CEA
levels (P = 0.001) significantly influenced recurrence of
colon adenocarcinoma, whereas intravascular embolus,
histological differentiation, gender, age, and tumor size
didn't affect recurrence of tumors (P > 0.05). Expression
of SNCG in primary tumors (P = 0.023) was also signifi-
cantly associated with recurrence. There were 61 patients
developed tumor recurrence during the follow-up period.
While 37% of patients with SNCG positive primary
tumor developed tumor recurrence, only 22% of patients
with SNCG negative tumors developed tumor recurrence
(P = 0.02).
SNCG overexpression correlates with poor outcome and is 
an independent prognostic indicator
To study whether SNCG is a prognostic factor for colon
cancer, we correlated SNCG expression in tumors with a
median follow-up of 44 ± 28 months (range 11 days to
121 months) after colon cancer surgery. We found a
strong association between SNCG and survival. SNCG-
positive patients showed a significantly poorer prognosis
than SNCG-negative patients in Kaplan-Meier analysis of
disease free survival (DFS) and overall survival (OS) (Fig-
ure 1E, F). While the cumulative proportions of DFS and
OS at 5 year after surgery were 58.0% ± 4.3%, 58.7% ±
4.4% in the SNCG-negative group, for the SNCG-positive
group, those of DFS and OS were reduced to 32.9% ±
6.2% and 32.5% ± 6.2%, respectively. The mean time for
DFS and OS was 78.7 ± 4.2 months [95% confidence
interval (CI), 70.5-86.9 months] and 80.3 ± 4.0 months
(95%CI, 72.4-88.2 months) in the SNCG negative group,
48.7 ± 5.4 months (95%CI, 38.1-59.3 months) and 51.1 ±
5.2 months (95%CI, 40.9-61.2 months) in the SNCG posi-
tive group (P  < 0.0001, respectively). We also found
SNCG levels were positively correlated with recurrence (r
= 0.141, P = 0.020) and inversely correlated with survival
(r = -0.221, P = 0.001, Spearman's correlation coefficient)
of patients with colon adenocarcinoma. The hazard ratio
of recurrence and death according to SNCG level wasLiu et al. BMC Cancer 2010, 10:359
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2.044 (95% CI, 1.114-3.752, P = 0.020) and 2.601 (95%CI,
1.471-4.601, P = 0.001).
Multivariate analysis revealed that SNCG was an inde-
pendent prognostic factor for DFS (P = 0.039) and OS (P
= 0.048) of the patients with colon adenocarcinoma.
SNCG level in colon adenocarcinoma tissue was predic-
tive for development of recurrence and a shorter DFS/
OS.
Combination of SNCG and CEA improves prognostic value 
of patients with colon adenocarcinoma
Since SNCG level was not associated with preoperative
serum CEA level, we were interested in studying whether
a combination of SNCG and CEA could improve prog-
nostic evaluation. As illustrated in Table 3, multivariate
analyses indicate that CEA, SNCG, and combination of
CEA and SNCG all remained independent prognostic
factors for DFS (P < 0.0001, 0.001, <0.0001) and OS (P <
0.0001, 0.001, <0.0001, respectively). Very importantly,
the hazard ratio of combined CEA and SNCG for DFS
and OS were 3.517 and 3.645, 2.440 and 2.639 for CEA,
and 2.213 and 2.141 for SNCG, respectively. These data
suggested that the combination of CEA and SNCG was a
strong prognostic indicator.
Figure 2 illustrates that 170 patients with SNCG posi-
tive (A), CEA positive (B), and either SNCG or CEA posi-
tive (C) all show significantly poorer survival rates than
those with the corresponding negative markers (P  =
0.001, <0.0001, <0.0001, respectively). A significant dif-
ference in survival rate was observed in 5-year follow up.
There were 59%, 63%, and 73% of DFS rates in patients
with SNCG-negative, CEA-negative, and both SNCG-
and CEA-negative, whereas SNCG-positive, CEA-posi-
tive, and either SNCG- or CEA-positive patients were
36%, 33%, and 37% (P = 0.001, <0.0001, <0.0001, respec-
tively). During the follow-up period, 43 of 170 (25%)
colon cancer patients were identified with postoperative
relapse. While 39% (24/62) patients with SNCG-positive,
38% (28/73) CEA-positive, and 34% (36/107) either
SNCG- or CEA-positive developed recurrence, only 18%
(19/108) patients with SNCG-negative, 16% (15/97) CEA-
negative, and 11% (7/63) both SNCG- and CEA-negative
patients developed postoperative relapse (P  = 0.002,
0.001, 0.001, respectively). The hazard ratio of recurrence
according to combined SNCG with CEA was 4.056
(95%CI, 1.679-9.800, P = 0.001), 2.958 for SNCG (95% CI,
1.452-6.028, P = 0.002) and 3.401 for CEA (95%CI, 1.648-
7.023, P = 0.001). Combination of CEA with SNCG might
improve prognostic evaluation for patients with colon
adenocarcinoma.
SNCG overexpression correlates with poor outcome and 
remains an independent prognostic indicator for patients 
with normal preoperative serum CEA level
SNCG was overexpressed in 35% (34/97) of adenocarci-
n o m a  t i s s u e s  f r o m  p a t i e n t s  w i t h  n o r m a l  p r e o p e r a t i v e
serum CEA level. SNCG-positive patients showed a sig-
nificantly poorer DFS rate than those SNCG-negative
patients (P = 0.002, Figure 2D). The DFS rate at 5 year
after surgery was 72% in the SNCG-negative group, and
46% in the SNCG-positive group. There were 42% (45/
108) of patients with elevated CEA levels in the SNCG
negative group, rates of DFS and OS of these patients
were 43% and 39% at 5 year after surgery. Univariate anal-
yses indicated that TNM stage (P < 0.0001), lymph node
metastasis (P  < 0.0001), intravascular embolus (P  =
0.013), and depth of invasion (P  = 0.044) significantly
impacted the DFS and OS of these patients. However, in
multivariate analysis, these factors were not correlative
with DFS and OS of the patients with normal preopera-
tive serum CEA level. In contrast, multivariate analysis
indicated that SNCG level was the most important inde-
Table 2: SNCG Expressing Profile in Colon Adenocarcinoma
cases SNCG expression Positive rate (%) P value
(-) (+)
Normala 194 190 4 2.1
Benignb 37 37 0 0
Colon adenocarcinoma tissues (n = 229)
Stage I 31 21 10 32.3 0.001#
Stage II 83 61 22 26.5 <0.0001#
Stage III 66 48 18 27.3 <0.0001#
Stage IV 49 25 24 49.0 <0.0001#
Total(I-IV) 229 155 74 32.3 <0.0001#
atumor-adjacent normal epithelium; bAdenoma, hyperplasia, and polyp tissues; #difference between adenocarcinoma tissues versus tumor-
adjacent normal epithelium tissues (paired T test).Liu et al. BMC Cancer 2010, 10:359
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Figure 1 Representative immunohistochemical staining for SNCG protein in human colon adenocarcinoma tissues (A-D) and Kaplan-Meier 
estimation of disease-free survival (E) and overall survival (F). A, SNCG expressed in the cytoplasm of colon cancer cells but not in the adjacent 
normal adenoepithelium. SNCG also expressed in colon neuron-chords, vascular endothelial cells, and smooth muscle cells of nearly all colon cancer 
specimens; B, C, and D represented the intensity of weak (1 score), moderate (2 scores) and strong (3 scores) staining of SNCG in cancer cytoplasm 
(original magnification 200×); E-F, Cases with SNCG-negative tumors (thick line) versus cases with SNCG-positive (thin line). SNCG-positive patients 
showed significantly poorer survival rates than those of SNCG-negative patients (P < 0.0001 by Log Rank (Mantel Cox) test). Numbers in the graph 
indicate percentages of DFS and OS at 5 year, respectively.
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pendent prognostic factor for DFS and OS (P = 0.001,
0.002), followed by tumor size (P = 0.020, 0.031) and dif-
ferentiation grade (P = 0.023, 0.038). The hazard ratio of
SNCG to DFS and OS were 3.491 and 3.132, while 2.734
and 2.545 for tumor size, and 2.372 and 2.035 for differ-
entiation (Table 4). The data showed that tissue SNCG
level was significantly correlated with patient clinical out-
come and independent of other clinicopathological
parameters for colon adenocarcinoma patients with nor-
mal preoperative serum CEA level.
Discussion
In the present study, we demonstrated that SNCG is an
independent prognostic factor of a shorter survival for
patients with colon adenocarcinoma. Although preopera-
tive serum CEA levels may provide independent prog-
nostic information [30], few studies have investigated the
surveillance of patients with normal preoperative serum
CEA levels. We investigated the impact of SNCG level on
the clinical outcome of patients with normal preoperative
serum CEA levels and our results demonstrated that
SNCG remained an independent prognostic variable for
these patients and affected patients' survival, but the clin-
icopathologic factors such as TNM stage, lymph node
metastasis, depth of invasion, all didn't influence the
patients' survival. Therefore, SNCG detection may repre-
sent a new prognostic tool for predicting relapse and sur-
vival outcome for patients with colon adenocarcinoma
and particularly for the patients with normal preoperative
serum CEA levels. We also demonstrated that combina-
tion of CEA and SNCG has a significant additive value
and provides a high prognostic value in colon cancer.
Tumor SNCG and preoperative CEA may provide mutual
complementary prognostic value and combined analyses
of SNCG with CEA provide a strong prognosis on sur-
vival outcome for patients with colon cancer.
SNCG levels in colon adenocarcinoma tissues are well
correlated with the presence of intravascular embolus,
but the impacts of SNCG on recurrence of tumor and on
DFS/OS of patients are greatly stronger than intravascu-
lar embolus. Venous invasion or lymph node metastasis
are generally recognized as prognostic clinicopathologic
variables for hematogenic recurrence, which is the most
frequent type of recurrence after surgery for CRC [31].
SNCG level in colon adenocarcinoma tissues may play a
major role in hematogenous metastasis. Previously, we
demonstrated that expression of SNCG in breast cancer
cells leads to a significant increase in motility and a pro-
found augmentation of metastasis in tumor xenograft
[12]. In addition, we recently demonstrated that patients
with SNCG-positive breast cancer have statistically
higher incidence for metastasis compared with patients
with SNCG-negative cancer [16]. It is anticipated that
SNCG-stimulated cell motility and metastasis is medi-
Table 3: Prognostic Value of Clinicopathological Factors, CEA, SNCG, and Combined CEA and SNCG on DFS and OS of 170 
Patients with Colon Adenocarcinoma
Characteristics DFS OS
HR (95% CI) P value HR (95% CI) P value
Univariate analysis
TNM stage (III/IV vs. I/II) 4.745 (2.873-7.837) <0.0001 4.667 (2.827-7.704) <0.0001
Depth of invasion(pT3 vs. pT1, T2) 3.539 (1.489-8.410) 0.004 3.507 (1.476-8.331) 0.004
Differentiation (PD vs. WD, MD) 1.733 (1.130-2.658) 0.012 1.741 (1.144-2.649) 0.010
LN metastasis(Positive vs. Negative) 3.701 (2.303-5.946) <0.0001 3.593 (2.237-5.771) <0.0001
Intravascular embolus(Positive vs. Negative) 1.933 (1.202-3.106) 0.006 2.021 (1.257-3.248) 0.004
CEA (Positive vs. Negative) 2.761 (1.739-4.383) <0.0001 2.776 (1.750-4.405) <0.0001
SNCG (Positive vs. Negative) 2.146 (1.367-3.368) 0.001 2.121 (1.351-3.331) 0.001
SNCG/CEA (either positive vs. both negative) 3.756 (2.097-6.729) <0.0001 3.811 (2.127-6.830) <0.0001
Multivariate analysis
TNM stage (III/IV vs. I/II) 3.251 (1.209-8.748) 0.020 3.904 (1.447-10.536) 0.007
Depth of invasion (pT3 vs. pT1, T2) 3.701 (1.449-9.450) 0.006 3.819 (1.488-9.805) 0.005
Differentiation (PD vs. WD, MD) 2.116 (1.309-3.422) 0.002 2.075 (1.313-3.299) 0.002
CEA (Positive vs. Negative) 2.440 (1.493-3.987) <0.0001 2.639 (1.615-4.315) <0.0001
SNCG (Positive vs. Negative) 2.213 (1.391-3.520) 0.001 2.141 (1.349-3.401) 0.001
SNCG/CEA (either positive vs. both negative) 3.517 (1.936-6.389) <0.0001 3.645 (2.005-6.629) <0.0001
WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated; LN, lymph node; HR, hazard ratio; CI, confidence interval.Liu et al. BMC Cancer 2010, 10:359
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ated at least by its chaperoning activity on stimulation of
activated (GTP-bound) form of Rho family members
[32].
Previous studies indicate that SNCG expression follows
a stage specific in breast cancer. While 71.4% of advanced
breast cancers are positive for SNCG expression, only
26.8% of stage I/II breast cancers are positive for SNCG
expression and 5.2% of benign hyperplasia expresses
SNCG. SNCG protein is not detectable in normal tissue
adjacent to breast cancer [16]. Similar studies also dem-
onstrated that SNCG expression was stage-specific in
many different cancer types [15]. However, in this study,
we did not find any correlation between SNCG level and
TNM stage. Relationship between SNCG level and TNM
stage needs a further investigation. Interestingly,
although our results revealed that elevated preoperative
serum CEA level had a better prognostic value for the
patients with stages I-II than the corresponding tissue
SNCG level, SNCG levels predict the poor clinical out-
come better than CEA level for patients with stages III-
IV. These studies clearly demonstrated that SNCG may
be useful as a prognostic indicator, especially important
for patients with stages III-IV.
Figure 2 Kaplan-Meier estimation of disease-free survival (DFS) for colon adenocarcinoma patients. A-C, DFS in patients (n = 170) according 
to SNCG level, CEA level, and combined CEA with SNCG. Patients with SNCG positive (A), CEA positive (B), either SNCG or CEA positive (C) all showed 
significantly poorer DFS rates than those with the corresponding negative factors (P = 0.001, <0.0001, <0.0001, respectively by Log Rank (Mantel Cox) 
test). D, DFS in 97 patients with normal preoperative serum CEA level. SNCG-positive patients had a significantly poorer survival rate than those SNCG-
negative patients (P = 0.002 by Log Rank (Mantel Cox) test). Numbers in the graph indicate percentages of DFS at 5 year, respectively.
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Tissue-based markers have been investigated for poten-
tial prognostic and predictive value. The most widely
studied tissue markers in CRC are thymidylate synthase,
microsatellite instability, p53, K-ras and deleted in col-
orectal cancer (DCC), but they have not currently been
recommended in routine practice for determining prog-
nosis or predicting response to therapy [4]. More accu-
rate screening tests for CRC should be developed,
including enhancing sensitivity of existing tumor markers
and identifying new prognostic markers. Our immuno-
histochemical results showed that SNCG predominantly
expressed in cytoplasm of colon cancer cells, but rarely in
adjacent normal epithelium, which are consistent with
previous report [25]. For some cancer cells, positive
SNCG staining was also observed in nucleus and mem-
brane, suggesting that SNCG is not an exclusively cyto-
plasmic protein. It has been previously reported that
SNCG localizes to spindle poles [33] and translocates
from perinuclear area to nucleus [34]. We also found that
SNCG was highly expressed in colon neuron-chords, vas-
cular endothelial cells and smooth muscle cells, but the
biochemical and cellular function is still unknown.
Conclusions
Our study demonstrated for the first time that tissue
SNCG was an important prognostic indicator of shorter
DFS/OS for CRC patients, especially for those with nor-
mal preoperative serum CEA level. SNCG level in colon
adenocarcinoma is potentially valuable in predicting
colon adenocarcinoma patients at high risk of recurrence
and shorter survival after surgery. Tumor SNCG and pre-
operative CEA levels are mutually complementary prog-
nostic factors and their combination improves prognostic
evaluation of colon adenocarcinoma patients compared
with each molecular marker alone. Interestingly, although
SNCG gene does not have a signal peptide, suggesting it
is not a secreted protein, a secreted form SNCG can be
detected in serum [25,26] and urine [27] samples of
malignant tumors. The potential application of serum
levels of SNCG for diagnosis and prognosis of colon ade-
nocarcinoma warrants further investigation.
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